Market revenue in 2023 | USD 1,305.4 million |
Market revenue in 2030 | USD 2,119.5 million |
Growth rate | 7.2% (CAGR from 2023 to 2030) |
Largest segment | Biopharmaceuticals |
Fastest growing segment | Biopharmaceuticals |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pharmaceuticals, Biopharmaceuticals |
Key market players worldwide | Boehringer Ingelheim, Novartis AG ADR, Regeneron Pharmaceuticals Inc, Pfizer Inc, Bristol-Myers Squibb Co, Roche Holding AG, UCB SA, Johnson & Johnson, Amgen Inc, AbbVie Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rheumatoid arthritis therapeutics market will help companies and investors design strategic landscapes.
Biopharmaceuticals was the largest segment with a revenue share of 88.74% in 2023. Horizon Databook has segmented the UK rheumatoid arthritis therapeutics market based on pharmaceuticals, biopharmaceuticals covering the revenue growth of each sub-segment from 2018 to 2030.
The UK rheumatoid arthritis therapeutics market is experiencing advancements and innovations, such as the establishment of a University of York spinout company, Mesenbio. Founded in January 2024, Mesenbio is focused on developing a groundbreaking treatment for adults and children suffering from RA.
The company aims to harness the potential of engineered human stem cells to produce a novel therapeutic approach that addresses the root causes of the disease instead of symptomatic treatment. RA affects nearly half a million people in the UK, leading to joint pain and inflammation in various body parts, such as the hands, knees, elbows, ankles, and wrists.
It is an autoimmune disease; the body's immune system attacks its cells, resulting in inflammation and tissue damage. While current therapies aim to alleviate pain and inflammation, they often fail to provide comprehensive treatment by not effectively reducing inflammation and protecting tissues from further damage.
Horizon Databook provides a detailed overview of country-level data and insights on the UK rheumatoid arthritis therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into UK rheumatoid arthritis therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account